Financial Performance - Operating revenue for the first nine months of 2023 was CNY 131,282,869.50, a decline of 4.85% from CNY 137,979,314.23 in the same period of 2022[11] - Net profit attributable to shareholders increased by 16.72% to CNY 37,442,324.30 for the first nine months of 2023, compared to CNY 32,078,508.50 in the previous year[11] - Basic earnings per share decreased by 22.41% to CNY 0.41 for the first nine months of 2023, compared to CNY 0.53 in the same period of 2022[11] - Total operating revenue for the first nine months of 2023 was CNY 131,282,869.50, a decrease from CNY 137,979,314.23 in the same period of 2022, representing a decline of approximately 4.9%[38] - Total operating costs for the first nine months of 2023 were CNY 96,371,658.16, slightly up from CNY 95,671,750.73 in 2022, indicating an increase of about 0.7%[38] - Net profit for the first nine months of 2023 reached CNY 43,049,386.21, compared to CNY 39,019,064.34 in 2022, reflecting a growth of approximately 10.4%[39] Assets and Liabilities - Total assets decreased by 7.93% to CNY 586,155,479.55 as of September 30, 2023, compared to CNY 636,611,335.69 at the end of 2022[11] - The company’s total liabilities to assets ratio was 8.35% as of September 30, 2023, down from 8.94% at the end of 2022[11] - The company's total liabilities decreased from approximately 56.92 million CNY at the end of 2022 to about 48.93 million CNY as of September 30, 2023[32] - The company's equity attributable to shareholders decreased from approximately 554.69 million CNY at the end of 2022 to about 513.46 million CNY as of September 30, 2023[32] Cash Flow - Cash flow from operating activities decreased by 22.85% to CNY 32,948,415.96 in the first nine months of 2023, down from CNY 42,707,135.05 in the same period last year[11] - The net cash flow from investment activities was negative at CNY -264,734,769.20, a decrease of 531.44% due to the purchase of structured deposits[13] - Cash flow from financing activities resulted in a net outflow of -CNY 81,485,205.23, contrasting with a net inflow of CNY 304,074,536.00 in the previous year[48] - The total cash and cash equivalents at the end of the period stood at CNY 153,067,664.75, down from CNY 331,381,630.23 at the end of the previous year[48] Research and Development - R&D expenses rose by 39.41% to CNY 13,057,607.36, primarily due to an increase in personnel and commissioned research expenses[12] - Research and development expenses for the first nine months of 2023 were CNY 13,057,607.36, up from CNY 9,366,565.59 in 2022, marking an increase of about 39.5%[39] - R&D expenses for Q3 2023 amounted to ¥10,320,764.68, an increase from ¥7,552,799.28 in Q3 2022, reflecting a growth of approximately 36.9%[43] Shareholder Information - The total number of unrestricted shares increased from 37,456,441 to 44,584,441, representing a rise from 40.93% to 48.72% of total shares[16] - The total number of restricted shares decreased from 54,059,500 to 46,931,500, reflecting a decline from 59.07% to 51.28% of total shares[17] - The number of core employees' shares increased from 5,020,126 to 5,616,196, which is an increase from 5.49% to 6.14% of total shares[17] - The company plans to repurchase between 2,400,000 and 3,800,000 shares, representing 2.62% to 4.15% of the total share capital, with a maximum repurchase price set at 14 CNY per share[24] - As of the reporting period, the company has repurchased 2,400,000 shares at an average price of 12.78 CNY per share, totaling approximately 26.11 million CNY, which is 51.28% of the upper limit of the planned repurchase fund[25] Other Financial Activities - The company reported a significant increase in other income, which rose by 5,535.26% to CNY 12,026,030.78, mainly from government subsidies received[12] - The company has engaged in a share buyback program, with multiple announcements made regarding this initiative[21] - The company purchased bank wealth management products totaling over 150 million at any point in time[23] - There are no pledged or frozen assets reported for the company during this period[19] - The company has made commitments that are being fulfilled without any breaches as of August 23, 2023[26] - The company has initiated new projects, including construction in progress valued at approximately 4.13 million CNY[31]
新芝生物(430685) - 2023 Q3 - 季度财报